Regional Medical Director, Value and Access - East

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit

The Regional Medical Director, Value and Access is a senior, field-based Medical Affairs leader who develops and executes the regional medical value strategy and serves as a scientific and strategic partner to payers, pharmacy benefit managers (PBMs), integrated delivery networks (IDNs), accountable care organizations (ACOs), Medicaid stakeholders, health technology assessment (HTA) bodies, and other population-health decision-makers. The role leads unbiased scientific exchange, translates clinical, health-economic, and real-world evidence into decision‑relevant value narratives, and shapes regional priorities that support formulary evaluation, coverage, reimbursement readiness, and patient access.

Operating with substantial autonomy, the Regional Medical Value Director partners closely with Field Medical, Market Access, HEOR/RWE, Clinical Development, Regulatory, and Policy. The role is especially critical in pre‑launch, launch, and lifecycle management, where it builds scientific credibility with priority payers and anticipates their evidence needs.

• Develop and execute a regional stakeholder engagement plan aligned with medical, evidence, and corporate priorities.
• Build peer‑to‑peer scientific relationships with senior clinical and population‑health leaders across national and regional health plans, PBMs, Medicaid organizations, IDNs, ACOs, employer coalitions, and HTA bodies.
• Serve as the senior scientific contact for complex payer and reimbursement questions, including pre‑launch and launch engagements.
• Lead balanced, non‑promotional exchange on disease state, clinical data, guidelines, safety and efficacy, comparative evidence, HEOR, RWE, and pipeline information where appropriate.
• Plan and run payer advisory boards and scientific forums, and ensure insights are captured and acted…